NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Nkarta, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.75−0.05 (-2.78%)
Close on Oct 19, 2026
- Market cap
- $130.37M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -61.8% | -28.9% | |
| Return on assets | – | -47.3% | -23.0% | |
| Current ratio | – | 36.10 | 12.69 | |
| Diluted shares | – | 17M | 74M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nkarta generated $399.48M from operations and spent $85.90M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$399.48M
Used
$85.90M
Capital expenditure$85.90M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$104.08M
- Cash generatingOperating cash flow above zero-$88.70M
- Return on assets improvedROA up on the prior year-28.7% → -20.8%
- Earnings backed by cashOperating cash flow above net income-$88.70M vs -$104.08M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose14.45 → 12.69
- No dilutionShare count did not rise68M → 74M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00